Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Positive top-line results for VIBRANT Phase 2 clinical trial of verekitug in CRSwNP with once every 12 week dosing
-
Upstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with CRSwNP
-
Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
-
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at EACCI 2025
-
Upstream Bio to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
-
Upstream Bio Appoints Stacy Price as Chief Technology Officer
-
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
-
Upstream Bio to Present at Upcoming March Investor Conferences
-
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Upstream appoints Allison Ambrose as General Counsel